Cingulate (CING) Profit After Tax (2021 - 2026)
Cingulate's (CING) quarterly Profit After Tax came in at -$6.3 million in Q4 2025, down 0.67% YoY from -$6.3 million in Q4 2024, and up 14.55% on a QoQ basis from -$7.3 million in Q3 2025.
Cingulate (CING) Profit After Tax (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Profit After Tax data on file, last reported at -$6.3 million in Q4 2025.
- Quarterly Profit After Tax fell 0.67% year-over-year to -$6.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$22.4 million (down 35.57% YoY) and the FY2025 annual result came in at -$22.4 million, down 35.57% from the prior year.
- Profit After Tax climbed to -$6.3 million in Q4 2025, from -$7.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$1.3 million in Q1 2021 to a low of -$15.3 million in Q3 2021.
- A 5-year average of -$5.0 million and a median of -$4.4 million in 2022 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 73.66% in 2022, down 275.1% in 2022.
- Tracing CING's Profit After Tax over 5 years: stood at -$2.7 million in 2021, then sank by 73.53% to -$4.6 million in 2022, then slumped by 50.59% to -$6.9 million in 2023, then increased by 10.15% to -$6.2 million in 2024, then decreased by 0.67% to -$6.3 million in 2025.
- The last three Profit After Tax figures came in at -$6.3 million (Q4 2025), -$7.3 million (Q3 2025), and -$5.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | -5.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.87 Mn |
| Dec 31, 2025 | -6.27 Mn |
| Sep 30, 2025 | -7.34 Mn |
| Jun 30, 2025 | -4.98 Mn |
| Mar 31, 2025 | -3.85 Mn |
| Dec 31, 2024 | -6.23 Mn |
| Sep 30, 2024 | -4.13 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Mar 31, 2024 | -2.97 Mn |
| Dec 31, 2023 | -6.93 Mn |
| Sep 30, 2023 | -5.98 Mn |
| Jun 30, 2023 | -6.62 Mn |
| Mar 31, 2023 | -4.00 Mn |
| Dec 31, 2022 | -4.61 Mn |
| Sep 30, 2022 | -4.03 Mn |
| Jun 30, 2022 | -4.04 Mn |
| Mar 31, 2022 | -5.00 Mn |
| Dec 31, 2021 | -2.65 Mn |
| Sep 30, 2021 | -15.29 Mn |
| Jun 30, 2021 | -1.43 Mn |